BEIJING, Aug. 28, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that its board of directors (the "Board") has received a revised preliminary non-binding proposal letter (the "Revised Proposal Letter"), dated August 26, 2025, from a consortium ...

Core Viewpoint - LakeShore Biopharma has received a preliminary non-binding proposal from Oceanpine Capital to acquire all outstanding ordinary shares at a price of US$0.86 per share, representing a premium over recent trading prices [1][2][10]. Group 1: Proposal Details - The proposed purchase price of US$0.86 per Ordinary Share represents a premium of 10.3% to the last closing price on August 15, 2025, and an 11.4% premium to the average closing price over the last 15 trading days [2][10]. - Oceanpine Capital plans to fund the transaction using rollover equity and available cash, ensuring that the proposal is not subject to a financing condition [2][11]. - Oceanpine Capital has engaged White & Case LLP as its international legal advisor for the proposed transaction [2][12]. Group 2: Company Background - LakeShore Biopharma is a global biopharmaceutical company focused on developing vaccines and therapeutic biologics for infectious diseases and cancer, utilizing its proprietary PIKA® immunomodulating technology platform [5]. - The company operates in China, Singapore, and the Philippines, led by a management team with extensive local and global experience in the biopharmaceutical industry [5]. Group 3: Board's Response - The Board of LakeShore Biopharma has just received the proposal and will review it to determine the best course of action for the company and its shareholders [3][4].